KR100204433B1 - 4-아미노피리미딘 유도체 - Google Patents

4-아미노피리미딘 유도체 Download PDF

Info

Publication number
KR100204433B1
KR100204433B1 KR1019940021017A KR19940021017A KR100204433B1 KR 100204433 B1 KR100204433 B1 KR 100204433B1 KR 1019940021017 A KR1019940021017 A KR 1019940021017A KR 19940021017 A KR19940021017 A KR 19940021017A KR 100204433 B1 KR100204433 B1 KR 100204433B1
Authority
KR
South Korea
Prior art keywords
formula
compound
imidazolyl
thienyl
methylaminopyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019940021017A
Other languages
English (en)
Korean (ko)
Other versions
KR950005825A (ko
Inventor
이성재
요시타카 고니시
타라스 마시나 오레스트
기겐 곤도
딩웨이 팀 유
앤 미스코우스키 타마라
Original Assignee
우에노 도시오
오노 야쿠힝 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 우에노 도시오, 오노 야쿠힝 고교 가부시키가이샤 filed Critical 우에노 도시오
Publication of KR950005825A publication Critical patent/KR950005825A/ko
Application granted granted Critical
Publication of KR100204433B1 publication Critical patent/KR100204433B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1019940021017A 1993-08-26 1994-08-25 4-아미노피리미딘 유도체 Expired - Fee Related KR100204433B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11190693A 1993-08-26 1993-08-26
US8/111.906 1993-08-26

Publications (2)

Publication Number Publication Date
KR950005825A KR950005825A (ko) 1995-03-20
KR100204433B1 true KR100204433B1 (ko) 1999-06-15

Family

ID=22341063

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940021017A Expired - Fee Related KR100204433B1 (ko) 1993-08-26 1994-08-25 4-아미노피리미딘 유도체

Country Status (11)

Country Link
US (1) US5525604A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0640599B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH0789958A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100204433B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1109055A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE163647T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2130878C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69408750T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0640599T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2114662T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW273548B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9325217D0 (en) * 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
WO1997032583A1 (en) * 1996-03-08 1997-09-12 Smithkline Beecham Corporation Use of csaidtm compounds as inhibitors of angiogenesis
DE19644228A1 (de) * 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
KR100239800B1 (ko) * 1996-11-28 2000-03-02 손경식 4,5-디아미노 피리미딘 유도체 및 이의 제조방법
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
GB2338957B (en) * 1997-02-19 2001-08-01 Berlex Lab N-heterocyclic derivatives as nos inhibitors
IN188411B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1997-03-27 2002-09-21 Yuhan Corp
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
AU748087B2 (en) 1998-02-17 2002-05-30 Tularik Inc. Anti-viral pyrimidine derivatives
DE19819023A1 (de) 1998-04-29 1999-11-04 Merck Patent Gmbh Thienopyrimidine
KR100272471B1 (ko) 1998-11-17 2000-11-15 김선진 신규의 피리미딘 유도체 및 그의 제조방법
AU3078000A (en) * 1999-01-25 2000-08-07 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compounds and antitumor agents containing the same as the active ingredient
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
KR100546992B1 (ko) * 1999-04-09 2006-02-01 씨제이 주식회사 4,5-다이아미노 피리미딘 유도체 및 이의 제조방법
US7037916B2 (en) 1999-07-15 2006-05-02 Pharmacopeia Drug Discovery, Inc. Pyrimidine derivatives as IL-8 receptor antagonists
IL148291A0 (en) 1999-09-16 2002-09-12 Tanabe Seiyaku Co Aromatic nitrogen-containing 6-membered cyclic compounds
ATE314362T1 (de) 1999-10-12 2006-01-15 Takeda Pharmaceutical Pyrimidin-5-carboximidverbindungen, verfahren zur herstellung derselben und deren verwendung
AU2365001A (en) * 1999-12-24 2001-07-09 Bayer Aktiengesellschaft Isoxazolo pyrimidinones and the use thereof
US6943161B2 (en) * 1999-12-28 2005-09-13 Pharmacopela Drug Discovery, Inc. Pyrimidine and triazine kinase inhibitors
US6410726B1 (en) 2000-01-12 2002-06-25 Tularik Inc. Arylsulfonic acid salts of pyrimidine-based antiviral
US6525051B2 (en) 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
ES2346513T3 (es) 2000-07-24 2010-10-18 Krenitsky Pharmaceuticals, Inc. 5-alquinil pirimidinas sustituidas que tienen actividad neurotrofica.
IT1318674B1 (it) * 2000-08-08 2003-08-27 Nicox Sa Faramaci per l'incontinenza.
US6716851B2 (en) 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
AU2002228922A1 (en) * 2000-12-12 2002-06-24 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US7081470B2 (en) 2001-01-31 2006-07-25 H. Lundbeck A/S Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
US20040127502A1 (en) 2001-01-31 2004-07-01 Synaptic Pharmaceutical Corporation Use of GAL3 antagonist for treatment of depression
AU2002233706C1 (en) * 2001-02-26 2005-12-22 Tanabe Seiyaku Co., Ltd. Pyridopyrimidine or naphthyridine derivative
CN1310907C (zh) 2001-04-27 2007-04-18 全药工业株式会社 杂环化合物和以其为有效成分的抗肿瘤药
US6982259B2 (en) 2002-04-30 2006-01-03 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
CA2490148A1 (en) 2002-07-02 2004-01-15 F. Hoffmann-La Roche Ag 2, 5-substituted pyrimidine derivatives as ccr-3 receptor antagonists ix
JP4906715B2 (ja) * 2004-05-08 2012-03-28 ニューロジェン・コーポレーション ４，５−ジ置換−２−アリールピリミジン類
JP2008520713A (ja) 2004-11-17 2008-06-19 ミイカナ セラピューティクス インコーポレイテッド キナーゼ阻害剤
CN101137382B (zh) * 2005-03-11 2012-11-21 全药工业株式会社 含有杂环化合物作为活性成分的免疫抑制剂和抗肿瘤剂
WO2006123639A1 (ja) * 2005-05-18 2006-11-23 Asahi Kasei Pharma Corporation ピリミジン誘導体
US20060293343A1 (en) * 2005-05-18 2006-12-28 Asahi Kasei Pharma Corporation Pyrimidine derivatives
KR20140025610A (ko) * 2005-09-30 2014-03-04 미카나 테라퓨틱스, 인크. 치환된 피라졸 화합물
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
WO2008154026A1 (en) * 2007-06-11 2008-12-18 Miikana Therapeutics, Inc. Substituted pyrazole compounds
US20110124649A1 (en) * 2007-11-09 2011-05-26 The Johns Hopkins University Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders
CN102143951A (zh) * 2008-09-04 2011-08-03 田边三菱制药株式会社 三取代嘧啶化合物及其作为pde10抑制剂的用途
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
AU2012280725B2 (en) * 2011-07-07 2017-02-02 Merck Patent Gmbh Substituted azaheterocycles for the treatment of cancer
MX2014002542A (es) 2011-08-29 2014-07-09 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2015089218A1 (en) * 2013-12-10 2015-06-18 David Wustrow Monocyclic pyrimidine/pyridine compounds as inhibitors of p97 complex
PL3089971T3 (pl) 2014-01-01 2021-01-25 Medivation Technologies Llc Związki i sposoby ich zastosowania
CN106458996B (zh) 2014-01-20 2020-11-03 克里弗生物科学公司 作为p97复合物的抑制剂的稠合嘧啶
CN105294661B (zh) * 2015-07-27 2017-10-24 西南大学 5‑氟尿嘧啶苯并咪唑类化合物及其制备方法和应用
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992320A (en) * 1974-08-24 1976-11-16 Basf Aktiengesellschaft Manufacture of a modified titanium component for catalysts of the Ziegler-Natta type
US4018770A (en) * 1975-03-03 1977-04-19 Sterling Drug Inc. N-(2-(pyridinyl)-4-pyrimidinyl)-aminomethylenemalonates and analogs
US3992380A (en) * 1975-03-03 1976-11-16 Sterling Drug Inc. 5,8-Dihydro-5-oxo-2-(4-or 3-pyridinyl)pyrido[2,3-d]pyrimidine-6-carboxylic acids and esters
US4032523A (en) * 1975-03-03 1977-06-28 Sterling Drug Inc. 4-amino (or halo or hydroxy or hydrazino)-2-(pyridinyl)pyrimidines
DE3922735A1 (de) * 1989-07-11 1991-01-24 Hoechst Ag Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
WO1994007867A1 (en) * 1992-09-28 1994-04-14 Pfizer Inc. Substituted pyrimidines for control of diabetic complications
US5318975A (en) * 1993-02-16 1994-06-07 Berlex Laboratories, Inc. 5-pyrimdineamine derivatives

Also Published As

Publication number Publication date
TW273548B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1996-04-01
US5525604A (en) 1996-06-11
EP0640599B1 (en) 1998-03-04
KR950005825A (ko) 1995-03-20
ES2114662T3 (es) 1998-06-01
DE69408750T2 (de) 1998-07-23
DE69408750D1 (de) 1998-04-09
JPH0789958A (ja) 1995-04-04
CN1109055A (zh) 1995-09-27
DK0640599T3 (da) 1998-09-28
CA2130878C (en) 1999-03-23
EP0640599A1 (en) 1995-03-01
ATE163647T1 (de) 1998-03-15
CA2130878A1 (en) 1995-02-27

Similar Documents

Publication Publication Date Title
KR100204433B1 (ko) 4-아미노피리미딘 유도체
US10653674B2 (en) Multisubstituted aromatic compounds as inhibitors of thrombin
FI89355B (fi) Foerfarande foer framstaellning av terapeutiskt aktiva 1-aminobut-3-en-foereningar
AU751139B2 (en) Amide derivative
JP2657760B2 (ja) ４−アミノキナゾリン誘導体およびそれを含有する医薬品
DE60225341T2 (de) Neue 1,2,4-triazolverbindung
US4882342A (en) 5-alkylbenzimidazoles, method of use and pharmaceutical compositions
KR20080051157A (ko) 트리아릴카르복시산 유도체
BG108076A (bg) Ацилирани инданил амини и приложението им като фармацевтични средства
JP2006522125A (ja) プロテインキナーゼのインヒビターとして有用なチアゾール
US20040248950A1 (en) Apo ai expression accelerating agent
AU5570299A (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases
EP1223932A1 (en) Compounds and methods
JP2019509337A (ja) プラスメプシンｖ阻害薬としてのイミノチアジアジン二量体誘導体
RU2497811C2 (ru) Фенилимидазольные соединения
US20020052396A1 (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases
AU2005217174B2 (en) Hydrazide type compounds and the use thereof in pharmaceutical compositions for the treatment of cardiovascular diseases
JP2004521903A (ja) ＴＧＦ−β阻害剤としてのチアゾール化合物
CA1213279A (en) Thiomethylpyridine derivatives, process for the production thereof and medicaments containing them
KR20050007453A (ko) 피리딜아크릴산아미드 유도체를 함유하는포스포디에스테라아제 ⅳ 저해제
US6670382B2 (en) Hydroxyformamidine derivatives and medicines containing the same
JP3082243B2 (ja) 血管拡張活性を有するニトロ化合物
US5057613A (en) Novel thione dopamine beta hydroxylase inhibitors
FR2693196A1 (fr) Dérivés de benzopyranone ou de benzothiopyranone, procédé de préparation et composition pharmaceutique les contenant.
US5189052A (en) Thione dopamine beta hydroxylase inhibitors

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20030319

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20040330

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20040330